Results 241 to 250 of about 3,459,561 (335)

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6022-6033, July 2026.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Management of hypertension in chronic kidney disease. [PDF]

Clin Med (Lond)
Doulton T, Swift PA, Hiremath S.
europepmc   +1 more source

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5670-5683, July 2026.
ABSTRACT Aims We evaluated the impact of scenario‐based multifactorial control on the 3‐year incidence of fatal/non‐fatal cardiovascular disease (CVD) and associated healthcare costs in Asian patients with type 2 diabetes (T2D). Materials and Methods We applied the validated ‘ABC’ model to simulate the 3‐year impact of attaining multiple treatment ...
Lee‐Ling Lim, Eric S. H. Lau, Juliana N. M. Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, Siew‐Pheng Chan, Soo Lim, Andrea O. Y. Luk, Juliana C. N. Chan   +9 more
wiley   +1 more source

Reninoma: An Occult Etiology of Hypertension Requiring Repeated Diagnostic Evaluation and Managed by Tumor Enucleation: A Case Report. [PDF]

Clin Case Rep
Nguyen Thi Ngoc M, Nguyen Thi Thanh H, Nguyen Phan Nhat L, Nguyen The Nam H.   +3 more
europepmc   +1 more source

Screening and Diagnosis of Primary Aldosteronism in Patients Using Renin-Angiotensin System Inhibitors. [PDF]

J Clin Hypertens (Greenwich)
Wang Q, Dong H, Li HW, Zou YB, Jiang XJ.
europepmc   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5834-5847, July 2026.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Malignant reninoma with pulmonary metastasis and ATRX mutation treated with olaparib: a case report of specialized treatment. [PDF]

Front Immunol
Zi GR, Zhang DJ, He DL, Feng RL, Ke CX.
europepmc   +1 more source

Serum IGF‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6131-6141, July 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin‐like growth factor 1 (IGF‐1) regulates metabolic and vascular function, but its role in long‐term cardio‐kidney outcomes (CKO) in MASLD remains unclear.
Yongin Cho, Hye‐Sun Park, Tae Seop Lim, Jong Ho Jhee, Jong Hyun Jhee   +4 more
wiley   +1 more source

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6324-6333, July 2026.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney, Peter Rossing, Maria Eugenia Canziani, Maria Luiza Caramori, Ricardo Correa‐Rotter, Lisa Cronin, Christian Hugo, Bo Ji, Juliane Meyerhoff, Masaomi Nangaku, Arnold Silva, Dorothea Urbach, Shimoli V. Shah, Dick de Zeeuw, Katherine R. Tuttle   +14 more
wiley   +1 more source

Drug-specific risks of acute kidney injury associated with triple whammy therapy: a nationwide self-controlled case series study in Japan. [PDF]

J Pharm Health Care Sci
Kunitsu Y, Abe R, Ikuta K, Hira D, Nakagawa S, Tsuda M, Terada T.   +6 more
europepmc   +1 more source